Moreover, ERβ expression was found to be considerably elevated in cisplatin-resistant bladder cancer sublines (vs. respective control sublines), and immunoreactivity for ERβ was significantly more often detected in bladder tumors from patients who had not responded well to subsequent neoadjuvant cisplatin-based chemotherapy (22/31, 71%) than in those from responders (9/24, 38%) [117]. Here, ESR2 is linked to urinary bladder cancer.